Search results for "Soft-Tissue Sarcoma"

showing 3 items of 3 documents

Safety and efficacy of intensity-modulated radiotherapy in the management of spermatic cord sarcoma.

2017

International audience; Purpose. - Spermatic cord sarcoma is a rare disease, which management remains controversial due to the lack of guidelines. The standard therapeutic approach is surgical: wide soft-tissue resection with radical inguinal orchidectomy, The diagnosis is made during the analysis of the specimen. The high rate of local recurrence indicates adjuvant radiotherapy of the tumor bed. The aim of this series is to determine the efficacy and safety of postoperative intensity-modulated radiotherapy for spermatic cord sarcomas. Patients and methods. - Our series included five consecutive cases of spermatic cord sarcoma treated between 2011 and 2014. The indications for radiotherapy …

LeiomyosarcomaMaleOrgans at Risk[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imagingmedicine.medical_treatment030232 urology & nephrologyParatesticular tumor[ SDV.CAN ] Life Sciences [q-bio]/Cancer[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicine0302 clinical medicineMedicineOrchiectomy[ SDV.IB ] Life Sciences [q-bio]/BioengineeringPatternsFederationRapidarc[ SDV.IB.IMA ] Life Sciences [q-bio]/Bioengineering/ImagingCancerAged 80 and overSpermatic CordSarcomaRadiotherapy DosageLiposarcomaMiddle AgedRetroperitoneal Sarcoma3. Good healthmedicine.anatomical_structureTreatment OutcomeOncology030220 oncology & carcinogenesisGenital Neoplasms MaleSoft-Tissue Sarcoma[SDV.IB]Life Sciences [q-bio]/BioengineeringSarcomaRadiodermatitisReoperationmedicine.medical_specialtyPrognostic-Factors[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineSpermatic cord03 medical and health sciencesTherapeutic approachHumansRadiology Nuclear Medicine and imagingIMRTAgedRetrospective StudiesRadiotherapybusiness.industryCancermedicine.diseaseRadiation-TherapySurgeryRadiation therapyRadiotherapy Intensity-ModulatedNeoplasm Recurrence LocalbusinessLigationOrchiectomyRare diseaseFollow-Up StudiesCancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
researchProduct

CUL4A, ERCC5, and ERCC1 as Predictive Factors for Trabectedin Efficacy in Advanced Soft Tissue Sarcomas (STS): A Spanish Group for Sarcoma Research (…

2020

A translational study was designed to analyze the expression of nucleotide excision repair (NER) and homologous recombination (HR) genes as potential predictive biomarkers for trabectedin in soft-tissue sarcoma (STS). This study is part of a randomized phase II trial comparing trabectedin plus doxorubicin versus doxorubicin in advanced STS. Gene expression levels were evaluated by qRT-PCR, while CUL4A protein levels were quantified by immunohistochemistry. Expression levels were correlated with patients&rsquo

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtylcsh:RC254-282Articlepredictive biomarkers03 medical and health sciences0302 clinical medicinePredictive biomarkersInternal medicineGene expressionmedicineDoxorubicinTrabectedinbusiness.industrySoft tissue sarcomasoft-tissue sarcomalcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease030104 developmental biologyOncology030220 oncology & carcinogenesistrabectedinSoft-tissue sarcomaImmunohistochemistryCUL4ASarcomaERCC1CUL4AERCC1businessTrabectedinmedicine.drugCancers
researchProduct

Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin

2017

<b><i>Objectives:</i></b> Low body mass index (BMI) and/or low lean body mass have been shown to be risk factors for chemotherapy-related toxicities in a number of different cancers. However, no data are available regarding the role of BMI as a risk factor for developing toxicities related to the novel anticancer agent, trabectedin, in patients with soft-tissue sarcoma (STS). We evaluated the role of BMI as a risk factor for trabectedin-related toxicity in patients with STS. <b><i>Methods:</i></b> Data from 51 patients with metastatic/advanced STS treated with trabectedin after progression on ≥1 anthracycline ± ifosfamide regimen were retrospe…

AdultMaleOncologySarcopeniaCancer Researchmedicine.medical_specialtyNeutropeniaDioxolesNeutropeniaBody Mass Index03 medical and health sciences0302 clinical medicineThinnessRisk FactorsTetrahydroisoquinolinesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAnthracyclinesIfosfamide030212 general & internal medicineRisk factorAntineoplastic Agents AlkylatingTrabectedinAgedRetrospective StudiesAged 80 and overIfosfamideToxicitybusiness.industrySoft tissue sarcomanutritional and metabolic diseasesSarcomaGeneral MedicineMiddle Agedmedicine.diseaseOncology030220 oncology & carcinogenesisSoft-tissue sarcomaFemaleUnderweightmedicine.symptombusinessBody mass indexFebrile neutropeniaTrabectedinmedicine.drugOncology
researchProduct